NOVN Nasdaq 2020 - 06 - 17

Novan, Inc.

NOVN | $0.0941 -24.84% -32.91% 7.2M

(0.0% 1d) (0.0% 1m) (-92.6% 1y) (0.0% 2d) (0.0% 3d) (-24.8% 7d) (318.21% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 2,636,246
http://www.novan.com
Sec Filling | Patents | 42 employees

(US) Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline include SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.

dermatological antiviral

add to watch list Paper trade email alert is off

Press-releases

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Published: 2024-04-03 (Crawled : 14:30) - biospace.com/
LGND | $69.89 1.99% 2.06% 0

Health Technology

| -4.53% | O: -0.83% H: 3.14% C: 2.93%
pharmaceuticals commercialization therapeutics

Delisting of Securities of Nymox Pharmaceutical Corporation; Aridis Pharmaceuticals Inc.; Novan, Inc.; ViewRay, Inc.; 9 Meters Biopharma, Inc.; Nabriva Therapeutics plc; UTA Acquisition Corporation; AppHarvest, Inc.; Yellow Corporation; Proterra Inc.; Amyris, Inc.; Chain Bridge I; LatAmGrowth SPAC; and SpringBig Holdings, Inc. from The Nasdaq Stock Market
Published: 2023-09-07 (Crawled : 20:00) - globenewswire.com
AMRSQ | $0.0015 -95.0% 35K

Manufacturing

| -91.11% | O: -10.0% H: 16.05% C: 8.64%
VRAYQ | $0.0001 0.0% 600

Manufacturing

| -99.99% | O: 6.84% H: 13.6% C: -4.0%
NDAQ | $61.09 -0.18% -0.17% 860

Finance

| 18.25% | O: 0.0% H: 0.19% C: -0.45%
ARDS | $0.0635 -1.55% 0

Health Technology

| -31.03% | O: 0.0% H: 13.45% C: -12.07%
nasdaq acquisition pharmaceuticals therapeutics proterra market

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
Published: 2023-07-17 (Crawled : 13:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M

Health Technology

| -84.6% | O: -63.13% H: 2.09% C: -20.11%
LGND | $69.89 1.99% 2.06% 0

Health Technology

| 3.01% | O: 0.94% H: 1.74% C: 0.39%
sb206 agreement

Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
Published: 2023-07-17 (Crawled : 14:20) - biospace.com/
NOVN | $0.0941 -24.84% -32.91% 7.2M

Health Technology

| -84.6% | O: -63.13% H: 2.09% C: -20.11%
LGND | $69.89 1.99% 2.06% 0

Health Technology

| 3.01% | O: 0.94% H: 1.74% C: 0.39%
acquire

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
Published: 2023-06-05 (Crawled : 13:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M

Health Technology

| -91.67% | O: 2.65% H: 4.31% C: -0.86%
update meeting

Novan Focuses Strategic Direction and Announces Restructuring
Published: 2023-05-31 (Crawled : 20:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M

Health Technology

| -93.08% | O: -8.82% H: 0.0% C: -9.68%

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-05-15 (Crawled : 11:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M

Health Technology

| -92.65% | O: -6.25% H: 1.58% C: -3.33%
update financial results

Novan to Report First Quarter 2023 Financial Results on May 15, 2023
Published: 2023-05-08 (Crawled : 13:20) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M

Health Technology